Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1 Apr 28, 2022 01:30AM
Press Release: Strong 2021 sales and business EPS growth enabling increased investment in R&D Feb 4, 2022 01:30AM
Press Release: Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity Feb 3, 2022 11:00AM
Sanofi : Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER(1) Oct 28, 2021 01:30AM
Sanofi (SNY) announces FDA approves Nexviazyme, an important new treatment option for late-onset Pompe disease Aug 6, 2021 11:45AM
View Older Stories

Aug 6, 2021 11:42AM FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease
Jul 29, 2021 01:30AM Sales growth accelerated - Full-year guidance raised
Jun 18, 2021 09:45AM European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis
Apr 28, 2021 01:30AM Sanofi poursuit sa trajectoire de croissance. Forte hausse du BNPA des activités(1) au T1 2021 à TCC
Feb 5, 2021 01:30AM T4 2020: Croissance du BNPA des activités(1) de près de 10% à TCC
Oct 29, 2020 02:30AM Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER
Sep 9, 2020 07:00AM Sanofi Genzyme continues research to improve the lives of patients with multiple sclerosis, with new data presented at MSVirtual2020
Jul 29, 2020 08:00AM Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation
Jul 29, 2020 01:30AM Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation
Jun 14, 2020 01:17PM Sobi and Sanofi Donate up to 500 Million Additional IUs of Clotting Factor to WFH Humanitarian Aid Program
Jun 14, 2020 10:58AM Sanofi and Sobi donate up to 500 million additional IUs of clotting factor to WFH Humanitarian Aid Program
May 29, 2020 01:00AM Sanofi names new leaders to Executive Committee
Apr 24, 2020 07:00AM Sanofi at forefront of fight against COVID-19 in Q1 2020
Apr 24, 2020 01:30AM Sanofi at forefront of fight against COVID-19 in Q1 2020
Apr 17, 2020 01:00AM Sanofi to present Phase 2 detailed results of its brain-penetrant BTK inhibitor in relapsing multiple sclerosis
Feb 6, 2020 08:00AM Sanofi delivers strong 2019 business EPS growth of 6.8% at CER
Feb 6, 2020 01:30AM Sanofi delivers strong 2019 business EPS growth of 6.8% at CER
Feb 6, 2020 01:30AM Sanofi delivers strong 2019 business EPS growth of 6.8% at CER
Oct 31, 2019 08:00AM Sanofi Q3 well on track
Oct 31, 2019 02:30AM Sanofi Q3 well on track
Jul 29, 2019 08:00AM Sanofi delivered solid growth in Q2 2019
Jul 29, 2019 01:30AM Sanofi delivered solid growth in Q2 2019
Apr 26, 2019 08:05AM Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER
Apr 26, 2019 01:31AM Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER
Feb 7, 2019 08:00AM Sanofi delivers 2018 business EPS growth of 5.1% at CER
Feb 7, 2019 01:32AM Sanofi delivers 2018 business EPS growth of 5.1% at CER
Feb 6, 2019 11:53AM FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
Feb 6, 2019 11:45AM Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
Oct 31, 2018 08:00AM Sanofi Q3 2018 Performance Confirms Return to Growth
Oct 31, 2018 02:32AM Sanofi Q3 2018 Performance Confirms Return to Growth
Oct 19, 2018 05:59PM Sanofi: FDA approves asthma indication for Dupixent® (dupilumab)
Oct 19, 2018 05:55PM FDA approves asthsma indication for Dupixent® (dupilumab)
Sep 28, 2018 04:41PM Sanofi : FDA approves Libtayo® (cemiplimab) as first and only treatment for advanced cutaneous squamous cell carcinoma
Sep 13, 2018 06:01AM Sanofi to refocus two global business units
Sep 3, 2018 08:00AM Cablivi™ (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
Jul 31, 2018 07:59AM Q2 2018 Performance Positions Sanofi for New Growth Phase
Jul 31, 2018 01:57AM Sanofi: Q2 2018 Performance Positions Sanofi for New Growth Phase
Jun 29, 2018 01:01AM Sanofi: CHMP recommends approval of Cablivi(TM) (caplacizumab)
Apr 27, 2018 07:15AM Sanofi: First-quarter 2018 Business EPS up 1.4% at CER
Apr 27, 2018 01:32AM Sanofi: First-quarter 2018 Business EPS(1) up 1.4% at CER
Feb 7, 2018 07:38AM Sanofi Delivers 2017 Business EPS in line with Guidance
Feb 7, 2018 03:45AM Sanofi Delivers 2017 Business EPS(1) in line with Guidance
Jan 7, 2018 03:01PM Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance
Dec 18, 2017 07:01AM Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis
Dec 15, 2017 07:03AM Sanofi (SNY) and Alnylam (ALNY) Announce FDA Lifted Clinical hold on Fitusiran
Dec 15, 2017 07:01AM Sanofi: FDA lifts clinical hold on fitusiran
Dec 7, 2017 08:00AM Sanofi explores combination treatments for multiple myeloma in new late-stage trials
Nov 9, 2017 07:00AM Sanofi, Principia agree to develop multiple sclerosis drug candidate
Nov 2, 2017 10:46AM Sanofi and Alnylam present positive complete results from APOLLO Phase 3 study of investigational patisiran in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy
Nov 2, 2017 08:19AM Sanofi: Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed
View Older Stories